about
Barriers to a cure for HIV in womenLow body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsPregnancy and virologic response to antiretroviral therapy in South AfricaAsking the right questions: developing evidence-based strategies for treating HIV in women and childrenLooking at Complicating Non-Biological Issues in Women with HIVDyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapyImpact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study.Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Incident pregnancy and time to death or AIDS among HIV-positive women receiving antiretroviral therapyFactors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The NetherlandsSex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Prevalence of drug resistance and associated mutations in a population of Hiv-1+ Puerto Ricans in 2005.Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and menGender differences in non-adherence among Brazilian patients initiating antiretroviral therapy.Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospitalFactors associated with HIV viral load suppression on antiretroviral therapy in Vietnam.Caring for women living with HIV: gaps in the evidence.Sex and gender in psychoneuroimmunology research: past, present and future.Gender differences in discontinuation of antiretroviral treatment regimens.Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.Predictors of HIV virological failure and drug resistance in Chinese patients after 48 months of antiretroviral treatment, 2008-2012: a prospective cohort study.Impact of Gender on Long-Term Treatment Outcomes of Highly Active Antiretroviral Therapy (HAART) in the TREAT Asia HIV Observational Database.Does the success of HIV treatment depend on gender?Sex differences in adherence to highly active antiretroviral therapy: a meta-analysis.Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite).Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.Progress towards the United Nations 90-90-90 and 95-95-95 targets: the experience in British Columbia, Canada.Gender and mental health aspects of living with HIV disease and its longer-term outcomes for UK heterosexual patients.Impact of gender on the risk of AIDS-defining illnesses and mortality in Danish HIV-1-infected patients: a nationwide cohort study.Pharmacokinetic properties of trifolirhizin, (-)-maackiain, (-)-sophoranone and 2-(2,4-dihydroxyphenyl)-5,6-methylenedioxybenzofuran after intravenous and oral administration of Sophora tonkinensis extract in rats.Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
P2860
Q26768632-010A181F-748D-4175-B10C-EAE7073252F0Q28535587-56999D6D-56A8-4B5E-869E-6FAA0E3FA670Q28741879-3E1E5610-19A8-4CDF-8241-30BD766D9406Q28743488-A76C2EB8-F8A0-46FC-A338-F67BA90D678AQ33736512-95A80F25-1D6C-440D-9988-F97FA58CD9C0Q33982131-EE692D36-C187-4024-B0D6-4DC42C36437AQ34226031-50D956EF-B126-422F-B90F-7B7DE803B947Q34472398-8B3A68DF-FE4B-474C-95F5-E90A11FB7B1EQ34474961-B8D07F82-9659-404C-98BF-8BE1CA38202CQ34495619-8AFC3A90-6ADF-46DB-8BB4-9799002115AEQ34631738-79ABF5DD-BA93-416D-8511-FACC6C193E1AQ34754376-6F539599-2EBB-4FC1-89D7-E0B046C57B84Q35010207-8CD3DC40-2BAB-49D4-BA78-D2C9B03D8557Q35093189-C832F12D-E429-433F-9D94-699C9CDB58A3Q35668307-55BABE67-E8DE-4FC7-B87D-949F5489B26CQ35944787-A1E8643E-7066-4362-BD8D-8B205425B6C5Q36016153-20B2D7EA-C390-4E71-A5BE-7D05683B0BDEQ36303839-AEDA4CB6-5559-4717-A360-44486DD1CD3CQ36844848-8DC57A7A-C16F-4EBE-A847-5FDDCC024E2EQ36865445-5880AC58-3519-4187-A7C0-B29F27019992Q37136270-FCAAF7C9-52A5-409E-8B1C-2DDAC3782B78Q37212049-51A3118C-CEDC-485E-A285-2F8816F96EF5Q37339475-D50BAFD8-538F-466E-AAE2-B11E5A376C64Q37440855-4EB8EADD-A0C7-4411-AC54-DCE4FBE2ECB8Q37691625-73B08059-69D2-4DD4-BB41-6521AD3FADB3Q37712960-FAD525CE-1CD1-46E8-9ED7-96B70E315110Q38422291-1CC616EC-6429-4A1F-B6BB-74D301190B9CQ38750666-561C2BC8-B0B2-4E50-A3DC-417681584C71Q39372748-EC9BB9DD-5E0E-4FAE-9DCB-EBB8FBDEE1FBQ40052482-E1CEFE44-40B9-4D4F-95A1-8F67C1AD3B87Q42587317-EA9EB10F-6B04-47AA-B3D3-2C2A405B6356Q43438000-1B06E0A1-7C91-45A2-B6BA-68111ECDBFBDQ45024810-378946BF-7294-4E62-8DD4-DB63E5ACAA22Q47133712-F6ED9C70-27FF-4A17-8D77-0FA804119263Q47359813-A6BA7C1A-2965-4F6B-8E80-0D69CDE03A9CQ47582376-D5684C65-7FC2-4B1E-A40E-D4558F239139Q48450425-BF1B1C62-0D22-4480-A484-D7EE3E8D9DADQ50556874-CEEFE46D-DEAF-4E68-8A91-FA69F9B54E01Q51016833-1167B1F1-0DE0-4A54-9A93-D89921205192Q51202282-14423329-7D01-4D1C-ABC3-52808D85A92D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Gender differences in the treatment of HIV infection.
@en
Gender differences in the treatment of HIV infection.
@nl
type
label
Gender differences in the treatment of HIV infection.
@en
Gender differences in the treatment of HIV infection.
@nl
prefLabel
Gender differences in the treatment of HIV infection.
@en
Gender differences in the treatment of HIV infection.
@nl
P2093
P1476
Gender differences in the treatment of HIV infection.
@en
P2093
Lucia Palmisano
Marco Floridia
Marina Giuliano
Stefano Vella
P304
P356
10.1016/J.PHRS.2008.07.007
P577
2008-07-30T00:00:00Z